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Methods: Older peoplewere invited to participate by their general practitioner practice. Eligible par-
ticipants were assessed for aMCI using an operationalized approach to the Petersen criteria and the
M@T and TYM.
Results: Both tests demonstrated significant ability in discriminating between people with aMCI and
controls (AUC5 0.91 for M@Tand 0.80 for TYM [P, .001 for both]). M@T performed with higher
sensitivity than TYM (85% vs. 63%) and similar specificity (84% vs. 87%). Both tests demonstrated
moderate test-retest reliability (k 5w0.5) and took ,10 minutes to administer.
Discussion: M@Tand TYM are quick to administer. M@T demonstrated higher diagnostic test ac-
curacy than TYM and could provide an efficient method for identifying aMCI in clinical and research
settings.
 2016 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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There has been a growing clinical and research interest in
the early identification of people at risk of developing de-
mentia. Mild cognitive impairment (MCI) has emerged as
a term to capture the predementia phase of cognitive
dysfunction [1] and is defined as “cognitive decline greater
than that expected for an individual’s age and education level
but that does not interfere notably with activities of dailyd no conflicts of interest.
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commons.org/licenses/by-nc-nd/4.0/).life” [2]. The amnestic form of MCI (aMCI), where the pre-
dominant symptom is memory impairment, is associated
with elevated rates of conversion to Alzheimer’s disease
(AD) [3]. It has been suggested that it may be more effective
to target interventions at people in this predementia phase of
AD, before the progressive disease is established [4].
Amnestic MCI is however largely unrecognized in pri-
mary care as its diagnosis depends on complex neuropsycho-
logical assessment methods not usually available in this
setting. There is a need for simple, quick, and sensitive
cognitive tests that will provide a more efficient way of iden-
tifying people with aMCI. These would provide a useful
resource to busy primary health care staff who are encour-
aged, as stated in UK national guidance, to refer peopleimer’s Association. This is an open access article under the CC BY-NC-ND
S. Ozer et al. / Alzheimer’s & Dementia 12 (2016) 987-995988who show signs of MCI for further assessment by memory
assessment services to aid early identification of dementia
[5]. They could also be applied by researchers to find suit-
able participants for enrollment into studies of candidate in-
terventions targeted at this early stage of cognitive decline.
A recent systematic review found that over 40 brief
cognitive tests have been developed and tested to identify
people with aMCI [6]. Several of these cognitive tests
demonstrated promising diagnostic test accuracy, although
most studies were found to be at a high risk of bias due to
the method of participant selection used. Most studies
selected patients with known aMCI from memory clinics
and compared their performance on the test under evaluation
with an opportunistically recruited group of people assumed
to have no cognitive impairment. This exposed the studies to
risk of unblinding of the patient assessment process and
potentially exaggerated diagnostic accuracy [7,8]. The
present study aimed to address this limitation by assessing
the validity of two brief cognitive tests in a cohort of
participants all recruited from the community, without
prior knowledge of their cognitive status, thereby reducing
the risk of bias in the assessment process.
The Memory Alteration Test (M@T) and the Test Your
Memory (TYM) test were selected for investigation in this
study. The developers of M@T, which is a brief,
interviewer-administered memory task, reported it to have
very high sensitivity (96%) and high specificity (70%–
79%) for discriminating between people with aMCI and
healthy controls [9,10]. The developers of TYM reported
that it had very high sensitivity (93%) and high specificity
(86%) for discriminating between people with and without
mild Alzheimer’s disease [11]. A subsequent study using a
Japanese version of the test highlighted its potential for
use as a screening tool for aMCI, reporting high sensitivity
(76%) and specificity (74%) [12]. The TYM has the added
advantage of being self-administered and requiring minimal
supervision.
The aim of the present study was to evaluate the effective-
ness of theM@Tand TYM for identifying people with aMCI
by investigating: (1) their sensitivity and specificity in de-
tecting aMCI in a community-based population in compari-
son with the widely used standard for diagnosing aMCI
based on the Petersen criteria [13]; (2) their test-retest reli-
ability performance; and, (3) their clinical utility, assessed
in terms of administration time and completion rates.2. Methods
2.1. Recruitment
Participants were recruited from nine Bradford, UK, gen-
eral practitioner practices (total registered patient population
of 85,870). Their primary care health records were first
screened to identify people who (1) were aged 70 years and
older; (2) were not resident in a care or nursing home; (3)
did not have dementia; (4) did not have current depression;(5) did not have history of stroke within the previous 3
months; (6) were not receiving palliative care. Study informa-
tion flyers were posted to these identified people. The flyer
asked further eligibility questions and those who responded
and met the following criteria (or required further clarifica-
tion) were contacted by telephone: (1) self-reported difficulty
with their memory; (2) spoke English; (3) had attended
school for at least eight years; (4) had an informant available
to answer some of the study questions. Additionally, 100 peo-
ple who did not self-report memory difficulties were invited
to take part. Further checks were carried out by phone to
ensure that the person was medically stable and could travel
to our research offices. The eligible volunteers subsequently
gave informed written consent to participate and enrolled
onto the study during a visit to their home. The study was
approved by the Yorkshire and The Humber National
Research Ethics Service Committee (ref: 12/YH/0207).2.2. Assessment
We developed a standardized protocol of neuropsycho-
logical tests to objectively assess for cognitive impairment,
and a classification consistent with aMCI was determined
according to the Petersen criteria [13]. The tests encom-
passed the cognitive domains of: memory (California Verbal
Learning Test (CVLT), 2nd Edition [14]), executive function
and attention (Brixton Spatial Anticipation Test [15] & Trail
Making Test Parts A & B [16]), visuospatial function (visual
object and space perception, spatial subset [17], and Clock
Drawing Test [16]) and language (Graded Naming Test
[18] & Pyramids and Palm Trees test [19]). Activities of
daily living (ADL) performance were assessed using the
informant-administered Bristol Activities of Daily Living
Scale [20]. In addition, the National Adult Reading Test
[21] was administered to provide an indication of pre-
morbid verbal IQ. Mood was also assessed, initially via
two depression screening questions [22,23] included in the
study information flyer. Later, these were removed from
the flyer and a more detailed assessment of mood was
completed using the Geriatric Depression Scale-short form
(GDS) [24], once the participant had been enrolled onto
the study. The GDS was administered to the majority
(93%) of participants. As low mood is known to impact on
memory performance, all those participants who scored
6 on the GDS were classified as having “low mood” and
were excluded from further analyses.
Participants who demonstrated impairment in memory
(defined as CVLT short delay and long delay free
recall  1.5 standard deviations below mean of published
norms) and no impairment in ADL were classified as
aMCI. Both single-domain (memory impairment only) and
multi-domain (memory impairment and one or more other
cognitive domain impairment) aMCI participants were
included.
The other possible classification categories after the neu-
rocognitive assessment process were (1) nonamnestic MCI
S. Ozer et al. / Alzheimer’s & Dementia 12 (2016) 987-995 989(impairment in non-memory cognitive domain(s)) and (2)
cognitive difficulties beyond MCI (impairment in one or
more cognitive domains and impairment in ADL).
Participants who did not meet the criteria for aMCI, or the
other possible study classifications, were classified as “con-
trols” and formed the reference group for the discriminatory
analyses.
2.3. Procedures
All participants were assessed using the M@T and the
TYM administered in a randomized order to avoid order ef-
fects, and the standardized battery of neuropsychological
tests described previously. One of the brief cognitive tests
was administered during session 1 which took place in the
participant’s home. The other brief cognitive test followed
by the neuropsychological test battery were administered
during session 2 which took place in our research facility
within two weeks of session 1. The M@T, TYM, and neuro-
psychological battery were all administered by research as-
sistants who were blinded to each other’s assessments. Both
the M@T and TYM were timed by stopwatch. Classifica-
tions of participants were agreed in consensus with the study
neuropsychologist (KN), who was blinded to the results
of the M@T and the TYM. To assess test-retest reliability,
session 3 was arranged for a sample of participants who
were re-administered the brief cognitive test they had
completed during session 1. Session 3 was scheduled to
take place at home within four weeks of session 1.
2.4. Memory Alteration Test
The Memory Alteration Test (M@T) [10] is an
interviewer-administered test comprising a minimum of 33,
and amaximum of 43, questions depending on free recall suc-
cess. It assesses five cognitive skills (encoding, orientation,
semantic memory, free recall, and cued recall, with recall in-
tervals of,10 minutes) with a maximum total score of 50. It
was developed and validated in Spain but has been translated
into English, although not validated in this form. The trans-
lated version from the development article was applied [10]
(with slight amendments made to the wording of some of
the semantic memory questions; see Supplementary Table 1).
2.5. Test Your Memory test
The Test Your Memory (TYM) test [11] is a supervised,
self-completed questionnaire comprising ten cognitive
tasks, providing assessment of a wider range of cognitive do-
mains than is covered in the M@T. In addition to memory
and orientation tasks, the TYM also includes calculation,
fluency, similarities, naming, and visuospatial tasks. As
with the M@T, the recall interval for the memory task is
,10 minutes. A score of five is also given for the amount
of help that the participant required to complete the task,
with higher scores indicating that less support was required.
The maximum total score is 50.2.6. Statistical analysis
All analyses were performed using SPSS statistics v22
(IBM). Between-group differences (aMCI vs. control) in
age, years of education, IQ, and the M@T and TYM scores
were explored using the Mann–Whitney U test (because the
data were non-normally distributed). Difference in gender
proportion between the groupswas analyzed using theX2 test.
Receiver operating characteristic (ROC) curve analysis
was applied to assess the ability of the M@T and TYM
global and subtest scores to discriminate between the
aMCI group and the control group for a range of cut-off
values. The area under the curve (AUC) was reported as a
single measure of overall accuracy. Optimal cut-off points
were defined as those providing the highest Youden index
(calculated as “sensitivity 1 (specificity 2 1)”) [25]. Posi-
tive and negative predictive values and likelihood ratios
were calculated for each optimal cut-off point.
Test-retest reliability of the M@T and TYM was investi-
gated using the established techniques of Bland and Altman
[26]. The mean difference between original test and retest
scores was calculated, as was the reliability coefficient,
which is twice the standard deviation of the differences
and provides a measure of random error. Paired sample t
tests were applied to explore for any significant differences
between original test and retest scores (because the data
were normally distributed). Agreement between original
test and retest classifications (based on optimal cut-off
scores) was also explored using the kappa statistic (estab-
lished categories for interpreting the kappa statistic were
applied from poor (,0.00) to moderate (0.41–0.60) to
almost perfect (0.81–1.00) [27].3. Results
From 1477 initial responses to the flyer, 507 participants
were recruited (see Fig. 1 for recruitment flow); 31 people
withdrew after session 1; and four people could not be clas-
sified (two had visual/hearing impairment that affected their
performance on the tasks and two could not complete the
assessment due to distress or fatigue). Thus, 472 participants
were assessed with the standardized battery of neuropsycho-
logical tests and classified. Seventy two percent of these par-
ticipants completed session 2 within two weeks of session 1.
Of the 472 participants classified, 52 (11.0%) people had
aMCI, 26 (5.5%) people had nonamnestic MCI, 14 (3.0%)
people had cognitive difficulties beyond MCI, and 20
(4.2%) people had low mood. The remaining 360 (76.3%)
people were designated controls and formed the reference
group for the subsequent analyses. The average individual
test scores from the standardized neuropsychological battery
of tests for the aMCI and control groups are provided as
Supplementary Material (see Supplementary Table 1).
The aMCI participants were significantly older, had fewer
years of education and a lower IQ than the controls (see
Table 1 and Supplementary Table 2). As these factors could
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17 declined to take part
603 INELIGIBLE*
(322 no informant; 214 no memory problems; 62 <8yrs schooling; 
54 +ve depression screen; 22 non-English speaking; 17 unable to 
travel; 3 no contact details provided; 2 visually impaired;1 
impaired memory due to cerebral aneurysm )
157 declined to take part
113 INELIGIBLE
(59 no informant; 14 unwell; 11 hearing/visual impairment; 11 
unable to travel; 10 dementia/possible dementia; 
6 <70 yrs; 1 no memory problems; 1 non-English speaking )
30 unable to contact
34 declined to take part
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(5 depression diagnosis; 4 unwell; 3 visual impairment; 2 no 
informant; 1 <70yrs; 1 lacked capacity to consent)
31 withdrew
4 excluded 
(2 hearing/ visual impairment; 2 assessment abandoned)
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Fig. 1. Recruitment flow through the study. (*some respondents were ineligible for .1 reason).
Table 1
Demographic characteristics and M@T & TYM test scores for aMCI and
Control participants
Characteristic/Score aMCI (n 5 52) Control (n 5 360) P value
Female, n (%) 26 (50) 162 (45) .6*
Age, y 78 (10) 75 (7) ,.001
Education, y 11 (2) 12 (4) .001
NART IQ 112 (19) 116 (13)y .02
M@T global score 35 (10)z 45 (5)x ,.001
TYM global score 41 (8) 47 (4)y ,.001
Abbreviations: NART, National Adult Reading Test; M@T, Memory
Alteration Test; TYM, Test Your Memory test.
NOTE. Data are presented as median (interquartile range) unless indi-
cated otherwise; P value for Mann–Whitney U test and *Chi-squared test.
yn 5 359.
zn 5 51.
xn 5 358.
S. Ozer et al. / Alzheimer’s & Dementia 12 (2016) 987-995990have had an influence on the M@T and TYM scores, age-
matched, education-matched, and IQ-matched controls
were randomly selected for the discriminatory analyses.
The aim was to select three matched controls for each
aMCI participant; however, some aMCI participants had
,3 matches (and some none at all), which resulted in 40
aMCI cases matched with 112 controls. The demographic
characteristics of these matched participants are provided
in Supplementary Table 3.3.1. M@T performance3.1.1. Validity
Participants with aMCI scored significantly lower on the
M@T than the control participants (35 (10) vs. 45 (5),
Fig. 2. (A) M@T and (B) TYM global scores for control and aMCI partic-
ipants. Abbreviations: o, mild outliers (i.e., data points that lie.1.5! IQR
away from the lower/upper quartile); *, extreme outliers (i.e., data points
that lie .3! IQR away from the lower/upper quartile); IQR, interquartile
range.
Fig. 3. Receiver operating characteristics of the (A) M@T and (B) TYM
for differentiating aMCI participants from age, education, and IQ-matched
controls.
S. Ozer et al. / Alzheimer’s & Dementia 12 (2016) 987-995 991U 5 1459, z 5 29.7, P , .001, see Table 1). The box plots
demonstrate the distribution of the M@T scores for each
group (see Fig. 2A).
Fig. 3A shows the ROC curve of the M@T for differenti-
ating the aMCI participants from the matched controls. The
AUCwas 0.91 and a score of 40 provided the optimal cut-off
for discriminating between aMCI and controls (sensitivity
85%, specificity 84%; see Table 2). At the developer-
recommended cut-off of 37 [10], a lower sensitivity (64%)
but higher specificity (96%) was achieved.
The diagnostic utility parameters for the M@T subtests
are also summarized in Table 2. The most sensitive subtests
to discriminate between the aMCI and control groups were
free recall and cued recall, which both demonstrated AUC
.0.85. Orientation was the least sensitive subtest, with the
lowest AUC value (0.61).3.1.2. Reliability
Twenty-five aMCI cases and 31 controls were reassessed
with the M@T. Three quarters (75%) of these participants
were reassessed within 4 weeks of session 1. Participants
tended to score higher in session 3 than session 1 (mean dif-
ference, 2.8 points (95% CI5 2.0 to 3.7); see Table 3). This
difference was significant (t (54) 5 26.05, P , .001). The
kappa value was 0.54 (indicating “moderate” agreement be-
tween sessions).
Table 2
Diagnostic utility of M@T and TYM to discriminate between aMCI and age, education and IQ-matched controls
Test (maximum scores) AUC (95% CI) P value Optimal Cut-off* Sensitivity Specificity PPV NPV LR1 LR2
M@T total score (50) 0.91 (0.85–0.96) ,.001 ,40 85 84 37 98 5.31 0.18
Encoding (10) 0.79 (0.70–0.87) ,.001 ,9 58 88 35 95 4.83 0.48
Orientation (5) 0.61 (0.50–0.71) .05 ,5 38 83 20 92 2.24 0.75
Semantic (15) 0.74 (0.65–0.83) ,.001 ,14 85 54 17 97 1.85 0.28
Free recall (10) 0.88 (0.82–0.94) ,.001 ,6 90 77 30 99 3.91 0.13
Cued recall (10) 0.86 (0.78–0.93) ,.001 ,9 80 78 29 97 3.64 0.26
TYM Total score (50) 0.80 (0.72–0.88) ,.001 ,43 63 87 35 95 4.85 0.43
Orientation (10) 0.57 (0.46–0.67) .22 ,10 30 83 16 91 1.76 0.84
Copying (2) 0.52 (0.41–0.62) .77 ,1 5 99 85 95 50.0 0.51
Semantic (3) 0.67 (0.56–0.77) .002 ,2 40 91 33 93 4.44 0.66
Calculation (4) 0.58 (0.47–0.69) .14 ,4 40 73 14 92 1.48 0.82
Fluency (4) 0.72 (0.63–0.82) ,.001 ,4 73 66 19 96 2.15 0.41
Similarities (4) 0.61 (0.51–0.72) .04 ,4 53 68 16 93 1.66 0.69
Naming (5) 0.54 (0.43–0.65) .46 ,5 13 96 27 91 3.25 0.91
Visuospatial 1 (3) 0.50 (0.40–0.61) .99 ,1 13 94 19 91 2.17 0.93
Visuospatial 2 (4) 0.53 (0.42–0.63) .65 ,4 15 90 14 91 1.50 0.94
Free recall (6) 0.72 (0.62–0.82) ,.001 ,3 50 93 44 94 7.14 0.54
Help (5) 0.53 (0.43–0.64) .55 ,4 13 93 17 91 1.86 0.94
Abbreviations: PPV, positive predictive value; NPV, negative predictive values; LR1, positive likelihood ratio; LR2, negative likelihood ratio.
PPV and NPV calculated for 10% prevalence of MCI.
*Cut-off providing highest Youden index.
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The median time to complete the M@T in the control
group was 6 min 5sec (IQR 5 1 min 40 sec). Participants
with aMCI took significantly longer than the control group,
with a median time of 8 min 15 sec (61 min 45 sec;
U 5 2798, z 5 27.95, P , .001).
The majority (n5 409, 99%) of aMCI and control partic-
ipants completed all the M@T questions. One aMCI partic-
ipant had one missing item from the free recall subset, and
two control participants each had one missing item from
the cued recall subset. In addition, one aMCI participant
had missing data from their retest M@T (three missing items
from the cued recall subset).
The M@T requires the participant to encode and recall
fivewords: cherry, axe, elephant, piano, and green. However,
it was noted that the words “axe” and “green” were
commonly misheard and had to be repeated.3.2. TYM performance3.2.1. Validity
Participants with aMCI scored significantly lower on the
TYM than the control participants (41 (8) vs. 47 (4),Table 3
Test-retest reliability of the M@T and TYM
Test
Bland and Altman results
Cohen’s
kappa
Mean
difference
95% CI for
mean difference SDdiff
Reliability
coefficient
M@T 22.8 22.0 to 23.7 3.5 6.9 (of 50) 0.54*
TYM 21.9 21.0 to 22.8 3.0 6.0 (of 50) 0.51*
*P , .001.U5 2921.5, z528.1, P, .001, see Table 1). The box plots
demonstrate the distribution of the TYM scores for each
group (see Fig. 2B).
Fig. 3B shows the ROC curve of the TYM for differen-
tiating the aMCI participants from the matched controls.
The AUC was 0.80, and a score of 43 provided the
optimal cut-off for discriminating between aMCI and con-
trols (sensitivity 63%; specificity 87%; see Table 2). At
the commonly used cut-off of 44 [12,28,29], a slightly
higher sensitivity (65%) but lower specificity (80%) was
achieved.
The diagnostic utility parameters for the TYM subtests
are summarized in Table 2. All subtests (except for the
Fluency subtest) performed with less sensitivity than the
global TYM test, and all subtests demonstrated AUC values
of ,0.75. Fluency and free recall were the most accurate
subtests, with AUCs of 0.72.
3.2.2. Reliability
Nineteen aMCI cases and 30 controls were reassessed
with the TYM. The majority (88%) of these participants
were reassessed within 4 weeks of session 1. Participants
tended to score higher in session 3 than session 1 (mean dif-
ference 5 1.9 points [95% CI 5 1.0 to 2.8]; see Table 3).
This difference was significant (t(48) 5 24.40,
P , .0005). The kappa value was 0.51 (indicating “moder-
ate” agreement between sessions).
3.2.3. Utility
The median time to complete the TYM in the control
group was 7 min 19 sec (62 min 30 sec). Participants with
aMCI took significantly longer (P , .005) than the control
group, with a median time of 9 min 26 sec (62 min 32sec;
U 5 4374.5, z 5 25.59, P , .001).
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all the aMCI participants and almost all the controls. Only
one control participant had missing items with four missing
items from the orientation subtest and no score for the help
given subtest.4. Discussion
This study aimed to assess the accuracy of two brief
cognitive tests (M@T and TYM) for identifying people
with aMCI in the community. The M@T performed with
higher diagnostic test accuracy than the TYM, with higher
sensitivity (85% vs. 63%), similar specificity (84% vs.
87%), and higher overall accuracy as demonstrated by the
AUC values (0.91 vs. 0.80). Both tests were associated
with a learning effect such that a second assessment repeated
within 1 month of the first-showed higher test scores. Both
tests were acceptable to participants with completion times
of ,10 minutes and very few missing items.
Although the M@T demonstrated reasonably high levels
of sensitivity and specificity for aMCI, the study did not
reproduce the very high diagnostic test accuracy (DTA) re-
sults reported in previous studies. For example, a recent
study by Custodio et al reported that a cut-off score of 37
had a sensitivity and specificity of 98% (AUC 5 0.999) to
differentiate aMCI from controls [30]. The developers of
the M@T recommend a cut-off score of 37, and they report
sensitivity of 96% and specificity of 70%–79% at this cut-off
[9,10]. However, we found a higher optimal cut-off value for
our sample (,40), and our data demonstrated a lower sensi-
tivity (63%) but higher specificity (96%) at the recommen-
ded cut-off.
Our DTA results for TYM also differed from those re-
ported in previous studies. A cut-off score of 44 has been rec-
ommended in three previous studies of TYM [12,28,29].
These studies report sensitivities of 74%–86% and
specificities of 60%–74% at this cut-off. We found a slightly
lower optimal cut-off value in our sample (,43) and lower
sensitivity (65%) but higher specificity (80%) at the previ-
ously recommended cut-off.
These DTA discrepancies might be explained by our
community-based recruitment method. The previous studies
were all conducted in secondary/specialist care settings such
as memory clinics [9,10,12], neurology departments [28,30],
or psychiatry units [29] and most recruited their aMCI sam-
ple from patients attending clinics and their “control” sam-
ple from a separate source, such as other hospital
departments or the wider community [10,12,29,30].
Studies which use a “case-control” design such as this are
known to exaggerate diagnostic accuracy [7,8]. The
present study used a sampling method that was designed to
reflect how the brief cognitive tests might be applied in
routine care in the future, that is, community-based aMCI
case finding (refined by self-reported questions on memory
difficulties). This approach has resulted in more conserva-
tive estimates of DTAwhich are likely to be more generaliz-able to unselected populations. Assessing all participants
with the same reference standard also meant that we avoided
verification bias which occurs when only a proportion of the
study population receives confirmation of the diagnosis
(usually those with positive test results) and can also result
in overestimation of DTA values [7,8]. The fact that both
tests were found to perform at lower sensitivity at the
recommended cut-offs than previously demonstrated indi-
cates that our aMCI population was less impaired than those
included in previous studies, likely to be a result of our
community-based, rather than secondary care-based,
approach to recruitment.
As reported by the developers of M@T, our study also
demonstrated that free recall and cued recall were the most
accurate subtests for discriminating between the aMCI and
control groups. It is perhaps unsurprising that these recall
scores are the most useful for identifying aMCI because it
is well known that episodic memory is impaired in aMCI
and early AD [31]. This is thought to be the result of early
pathologic changes that occur in the hippocampus and
medial temporal lobe [32]. Similarly, the Free Recall subtest
was found to be the most accurate TYM subtest for identi-
fying people with aMCI. Some TYM subtests were found
to be of less value in discriminating between aMCI and con-
trols (e.g., the naming subtest and two visuospatial subtests,
all with AUC valuesw0.5). These findings indicate that the
recall subtest scores are particularly useful for identifying
aMCI and that particular emphasis should be placed on these
subtests when interpreting scores.
It is important to note here that we applied an algorithmic,
rather than clinical, categorization of aMCI. Although this
differs from usual clinical practice, which would involve
the incorporation of clinical and neurological examination
to make a final diagnosis, it enabled us to apply the criteria
in a standardized and objective manner, thereby ensuring
reliability of our classifications [4]. The M@T and TYM
have both demonstrated that they are valid in identifying
people with aMCI as classified using this algorithmic
method. Of course, in practice, further clinical assessment
would be required to make a differential diagnosis, and it
is the intention that these instruments would be used as a first
screening stage in clinical practice and not as diagnostic
tools.
Both the M@T and TYM performed with moderate test-
retest reliability. Participants tended to score higher in the
second session than the first on both tests indicating that
there may have been a learning/practice effect. This is
commonly seen with repeated cognitive testing [33]. The
reliability coefficient (which reflects random error) was
fairly high for both tests at 6.9 and 6.0 points for M@T
and TYM, respectively. These values give an indication of
the maximum change in score on retest that might be ex-
pected by chance in the absence of change in an individual’s
cognitive status. In other words, only a change of score that
is more than seven points for M@T and six points for TYM
would represent real change for an individual patient. To the
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data. This is relevant if these tests are to be used in applica-
tions such as measuring the effectiveness of interventions or
monitoring change in cognition over time (although testing
intervals may be longer than four weeks in these instances,
which may lessen any practice effects).
Both tests were quick to administer, taking,10 minutes,
with the M@T being slightly quicker than the TYM (by
approximately 1 minute, on average). Furthermore, we
found very little missing data for both tests indicating that
there were no issues with administering them. Both tests
were designed to be administered by nonspecialist staff
(with the TYM requiring minimal supervision). A particular
issue with the M@T arose concerning the words used to
assess episodic memory. The words “axe” and “green”
were often misheard by the participants and had to be
repeated and so thesemay need to be replaced bymore easily
distinguishable words for use in English-speaking popula-
tions (e.g. “hammer”, “yellow”). Any adaptations of the
M@T would ideally need to be revalidated in further DTA
studies.
A limitation of the present study is that there was no long-
term follow-up of the participants and so the prognostic abil-
ities of the tests cannot be commented on here. Future
studies are required to see how accurate the tests are at
discriminating between those people who go on to develop
dementia and those who remain stable or improve. It would
also be interesting to evaluate how the M@T and TYM
might perform relative to other commonly used brief cogni-
tive tests, such as the Memory Impairment Screen [34] and
the Montreal Cognitive Assessment (MoCA) [35] in a
similar setting, and head-to-head comparative studies are
warranted in the future.
In summary, the present study has provided evaluation of
the performance of M@T and TYM within a community-
based UK setting, providing results that are generalizable
to the wider population. Amnestic MCI is largely unrecog-
nized in primary care due to the lack of simple, quick, and
sensitive cognitive tests. Both M@T and TYM were simple
and quick to use and demonstrated moderate test-retest reli-
ability. However, M@T was found to perform with higher
DTA than TYM and could provide an efficient and accurate
method for identifying aMCI in clinical or research settings.Acknowledgments
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1. Systematic review: Over 40 brief cognitive tests have
been developed to identify people with aMCI. How-
ever, these have mainly been tested in secondary care
settings with highly selected patient and control
groups. The Memory Alteration Test (M@T) and
Test Your Memory (TYM) test have both demon-
strated promising diagnostic test accuracy within
this context. This is the first study aimed at investi-
gating their performance in a community-based
setting.
2. Interpretation: Our community-based approach to
recruitment has resulted in more conservative esti-
mates of diagnostic test accuracy for the M@T and
TYM than previously reported. Nevertheless, the
M@T in particular has demonstrated significant
discriminative abilities and could provide an efficient
and accurate method for identifying aMCI in clinical
or research settings.
3. Future directions: The word list used to assess
episodic memory in the M@T could be improved
for English-speaking populations with any adapta-
tions to be revalidated in future studies. Further
studies are also required to investigate the prognostic
abilities of the tests.References
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